TAAR1 and infection: Tα1 could reduce, through the modulation of dendritic cells, the amount of proinflammatory cytokines produced by T cells. Moreover, Tα1 improve lymphocyte functionality and could become a beneficial therapeutic alternative as an adjuvant in SARS-CoV2 treatment either in the acute phase after infection or reinfection.